EPHA3 and hematologic disorder: Anti-EPHA2 monoclonal antibody DS-8895a has been tested on esophageal and gastric cancer patients and EPHA3 antibody IIIA4 (Ifabotuzumab/KB004) on GBM cases and patients with hematologic malignancies.